Skip to main content

RZPD Expands NimbleGen Array Services Offering to Include Affy IP


NEW YORK (GenomeWeb News) - The German Resource Center for Genome Research (RZPD), based in Berlin, said it has expanded an agreement with NimbleGen to cover Affymetrix’ microarray patents in Germany and Austria.
NimbleGen signed an agreement with Affymetrix in October that gave it non-exclusive, worldwide rights for the manufacture, use, and sale of nucleic acid microarrays.
Under the new agreement, RZPD will be able to offer technology covered by this IP to its customers as part of its services offering.
RZPD has been a distributor for NimbleGen in Germany and Austria for three years. It offers services such as ChIP-chp, comparative genomic hybridization, and gene expression analysis based on the NimbleGen platform.
The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.